We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+1.32%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.45B
AUM Growth
-$11.8M
Cap. Flow
-$571K
Cap. Flow %
-0.02%
Top 10 Hldgs %
40.31%
Holding
207
New
13
Increased
45
Reduced
58
Closed
10

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.47M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.05M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.91M
4
BSX icon
Boston Scientific
BSX
+$6.1M
5
GILD icon
Gilead Sciences
GILD
+$5.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$20.7M
2
ILMN icon
Illumina
ILMN
+$12.7M
3
ELV icon
Elevance Health
ELV
+$10.4M
4
CNC icon
Centene
CNC
+$6.81M
5
AGN
Allergan plc
AGN
+$6.78M

Sector Composition

Rank Sector Weight
1 Healthcare 95.11%
2 Real Estate 2.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MASI
101
DELISTED
Masimo
MASI
$4.13M 0.17%
27,732
+17,017
+159% +$2.34M
ARGX icon
102
argenx
ARGX
$53.4B
$4.02M 0.16%
28,381
– –
FOLD
103
DELISTED
Amicus Therapeutics
FOLD
$3.93M 0.16%
314,597
– –
HZNP
104
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.79M 0.15%
157,473
+138,123
+714% +$3.5M
THC icon
105
Tenet Healthcare
THC
$20.5B
$3.77M 0.15%
182,671
+41,535
+29% +$957K
PHG icon
106
Philips
PHG
$25.7B
$3.72M 0.15%
107,440
-2,582
-2% -$82.9K
SNY icon
107
Sanofi
SNY
$103B
$3.72M 0.15%
85,941
-93,959
-52% -$4M
MRUS
108
DELISTED
Merus
MRUS
$3.59M 0.15%
245,114
-72,557
-23% -$1.03M
GBT
109
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.55M 0.14%
67,516
-18,472
-21% -$1.06M
ALC icon
110
Alcon
ALC
$33.6B
$3.44M 0.14%
+55,369
New +$3.25M
NVCR icon
111
NovoCure
NVCR
$1.73B
$3.42M 0.14%
54,074
-11,890
-18% -$602K
ALBO
112
DELISTED
Albireo Pharma Inc
ALBO
$3.39M 0.14%
105,154
-19,846
-16% -$664K
BCEL
113
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3.3M 0.13%
+175,000
New +$3.16M
LIVN icon
114
LivaNova
LIVN
$4.4B
$3.29M 0.13%
45,681
+34,281
+301% +$2.51M
VAR
115
DELISTED
Varian Medical Systems, Inc.
VAR
$3.27M 0.13%
24,027
-2,200
-8% -$294K
MPT
116
Medical Properties Trust
MPT
$2.77B
$3.26M 0.13%
187,063
-139,000
-43% -$2.5M
TAK icon
117
Takeda Pharmaceutical
TAK
$54.6B
$3.15M 0.13%
178,128
– –
PTLA
118
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.13M 0.13%
115,448
– –
XNCR icon
119
Xencor
XNCR
$1.5B
$2.96M 0.12%
72,382
– –
DHC
120
Diversified Healthcare Trust
DHC
$2.15B
$2.96M 0.12%
357,720
– –
DGX icon
121
Quest Diagnostics
DGX
$25.7B
$2.65M 0.11%
26,012
-40,488
-61% -$3.89M
IQV icon
122
IQVIA
IQV
$38.7B
$2.64M 0.11%
16,391
– –
A icon
123
Agilent Technologies
A
$39.1B
$2.51M 0.1%
+33,600
New +$2.49M
NTLA icon
124
Intellia Therapeutics
NTLA
$1.49B
$2.46M 0.1%
150,290
– –
RARE icon
125
Ultragenyx Pharmaceutical
RARE
$2.45B
$2.44M 0.1%
38,480
-38,478
-50% -$2.45M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Tekla Capital Management held 207 positions worth $2.45B, down 0.48% from $2.46B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2019 filing shows 13 new, 45 increased, 58 reduced and 10 closed positions. Its largest new stake was Alcon: 55,369 shares worth $3.44M. The largest sale was Biogen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2019 buy was Alcon: 55,369 shares worth $3.44M.
  • Tekla Capital Management added most to Regeneron Pharmaceuticals in Q2 2019, an estimated $8.47M increase.
  • Tekla Capital Management's biggest Q2 2019 reduction was Biogen, cutting an estimated $20.7M.
  • Tekla Capital Management fully exited Centene in Q2 2019, selling an estimated $6.81M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.45B portfolio in Q2 2019.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q2 2019.
  • Tekla Capital Management's portfolio value fell 0.48% quarter-over-quarter to $2.45B.

Based on Tekla Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.